Optimi Health Appoints Chief Science Officer
(firmenpresse) - Company welcomes leadership oversight of new product research, formulations & trials
VANCOUVER, BC (May 26, 2021) - Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (Optimi or the Company), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce the engagement of Mr. Justin D. Kirkland to the position of Chief Science Officer with immediate effect.
Mr Kirkland is a chemist with specialized experience in natural products, small molecules, peptide synthesis, analytical chemistry, and drug formulations for improved bioavailability. He was recently awarded a U.S. patent for the improved synthesis of the ergoline, 2-bromo-LSD; useful in treating cluster headaches. He lately served as CEO of Las Vegas-based Fristoe Pharmaceuticals, an FDA registered wholesale drug distributor, and previously oversaw product development for Wells Pharmacy Network from their base in Florida; he was the lead scientific investigator regarding synthetic peptides at Tailor Made Health in Kentucky, and managed functional food manufacturing at Nuka Foods in Colorado and founded Kilochems efforts in Illinois. Since 2007, he founded and operated Nutraseeds dietary supplements and cosmetics program. Kirklands career includes training support, sales, analytics, and related consulting services since 1998.
Optimis JJ Wilson, (Chairman of the Board), states, We felt it important to invest time to find a suitable leader to oversee and coordinate the multiple and overlapping aspects of our research efforts. We were delighted to identify a candidate that fit with our approach of aggressively pursuing IP and patentable all-natural psilocybin formulations so readily. Justins overall background, interest, and experience in the development of innovative natural drug products is ideally suited to assist our rapid growth in the research and development of natural and novel psilocybin-based formulations. The fact he has extensive experience with functional product development and manufacturing is a significant plus as we begin our upcoming dosing study in humans at the University of Calgary. On behalf of the whole team, we welcome him and look forward to working together as we grow our business of human optimization.
As previously stated, Optimis overarching philosophy and commitment to the use of all-natural ingredients in its products is a key differentiator compared to those industry competitors who have committed to the production of laboratory produced synthetic psilocybin compounds. To further these efforts, the company is nearing completion and official commissioning of its 20,000 sq. ft. purpose-built facilities in Princeton, BC. This effort, along with an accelerated need to coordinate activities with the previously announced IMPACT program and research relationship with Numinus Wellness are extraordinary opportunities requiring effective leadership in order to rapidly meet the requisite steps towards the future commercialization of psilocybin-based formulations.
On Behalf of the Board of Directors, Optimi Health Corp.
Mike Stier
President, Chief Executive Officer and Director
ABOUT OPTIMI (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN)
Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealers license under Canadas Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production.
Find out more at: https://optimihealth.ca/.
FOR FURTHER INFORMATION CONTACT:
Investor Relations
Email: investors(at)optimihealth.ca
Phone: +1 (778) 930-1321
Web: https://optimihealth.ca/
FORWARDLOOKING STATEMENTS
This news release contains forwardlooking statements and forwardlooking information within the meaning of Canadian securities legislation (collectively, "forwardlooking statements") that relate to Optimis current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as "will likely result", "are expected to", "expects", "will continue", "is anticipated", "anticipates", "believes", "estimated", "intends", "plans", "forecast", "projection", "strategy", "objective" and "outlook") are not historical facts and may be forwardlooking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forwardlooking statements. No assurance can be given that these expectations will prove to be correct and such forwardlooking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward looking statements pertaining to the dealers license application, activities proposed to be conducted under the Companys research exemption and associated business related to Psilocybin and Psilocin and Optimis plans, focus and objectives.
Forwardlooking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimis control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forwardlooking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID19 pandemic and other factors set forth under ForwardLooking Statements" and Risk Factors in the Companys Final Prospectus dated February 12, 2021. Optimi undertakes no obligation to update or revise any forwardlooking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forwardlooking statement. Any forwardlooking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
" alt="Banxa Reports March Quarter Financial Results, Maiden Adjusted EBITDA and Record-setting Revenue">
" alt="Defense Metals Announces Plans for 2021 Wicheeda Rare Earth Element Deposit Resource Expansion and Definition Diamond Drill Program ">
Datum: 26.05.2021 - 09:03 Uhr
Sprache: Deutsch
News-ID 1567555
Anzahl Zeichen: 4979
contact information:
Contact person:
Town:
Wien
Phone:
Kategorie:
Business News
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 227 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Optimi Health Appoints Chief Science Officer
"
steht unter der journalistisch-redaktionellen Verantwortung von
Optimi Health Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
